These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 25174933)

  • 1. Gauging reactive metabolites in drug-induced toxicity.
    Eno MR; Cameron MD
    Curr Med Chem; 2015; 22(4):465-89. PubMed ID: 25174933
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic activation in drug-induced liver injury.
    Leung L; Kalgutkar AS; Obach RS
    Drug Metab Rev; 2012 Feb; 44(1):18-33. PubMed ID: 21939431
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Minimising the potential for metabolic activation in drug discovery.
    Kalgutkar AS; Soglia JR
    Expert Opin Drug Metab Toxicol; 2005 Jun; 1(1):91-142. PubMed ID: 16922655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extrahepatic targets and cellular reactivity of drug metabolites.
    Orhan H
    Curr Med Chem; 2015; 22(4):408-37. PubMed ID: 25174932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug metabolism and metabolite safety assessment in drug discovery and development.
    He C; Wan H
    Expert Opin Drug Metab Toxicol; 2018 Oct; 14(10):1071-1085. PubMed ID: 30215280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reactive Metabolites: Current and Emerging Risk and Hazard Assessments.
    Thompson RA; Isin EM; Ogese MO; Mettetal JT; Williams DP
    Chem Res Toxicol; 2016 Apr; 29(4):505-33. PubMed ID: 26735163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Are chemically reactive metabolites responsible for adverse reactions to drugs?
    Williams DP; Kitteringham NR; Naisbitt DJ; Pirmohamed M; Smith DA; Park BK
    Curr Drug Metab; 2002 Aug; 3(4):351-66. PubMed ID: 12093355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural alerts, reactive metabolites, and protein covalent binding: how reliable are these attributes as predictors of drug toxicity?
    Kalgutkar AS; Didiuk MT
    Chem Biodivers; 2009 Nov; 6(11):2115-37. PubMed ID: 19937848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analytical strategies for the screening and evaluation of chemically reactive drug metabolites.
    Wen B; Fitch WL
    Expert Opin Drug Metab Toxicol; 2009 Jan; 5(1):39-55. PubMed ID: 19236228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The generation, detection, and effects of reactive drug metabolites.
    Stachulski AV; Baillie TA; Park BK; Obach RS; Dalvie DK; Williams DP; Srivastava A; Regan SL; Antoine DJ; Goldring CE; Chia AJ; Kitteringham NR; Randle LE; Callan H; Castrejon JL; Farrell J; Naisbitt DJ; Lennard MS
    Med Res Rev; 2013 Sep; 33(5):985-1080. PubMed ID: 23090860
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detecting reactive drug metabolites for reducing the potential for drug toxicity.
    Grillo MP
    Expert Opin Drug Metab Toxicol; 2015; 11(8):1281-302. PubMed ID: 26005795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Toxicophores: investigations in drug safety.
    Williams DP
    Toxicology; 2006 Sep; 226(1):1-11. PubMed ID: 16860917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Reactive metabolites of xenobiotics : their role in the hepatotoxicity of drugs].
    Pessayre D; Benhamou JP
    C R Seances Soc Biol Fil; 1979; 173(2):458-68. PubMed ID: 159767
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predicting toxicities of reactive metabolite-positive drug candidates.
    Kalgutkar AS; Dalvie D
    Annu Rev Pharmacol Toxicol; 2015; 55():35-54. PubMed ID: 25292426
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conventional and novel approaches in generating and characterization of reactive intermediates from drugs/drug candidates.
    Orhan H; Vermeulen NP
    Curr Drug Metab; 2011 May; 12(4):383-94. PubMed ID: 21395525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High resolution mass spectrometry-based methodologies for identification of Etravirine bioactivation to reactive metabolites: In vitro and in vivo approaches.
    Godinho ALA; Martins IL; Nunes J; Charneira C; Grilo J; Silva DM; Pereira SA; Soto K; Oliveira MC; Marques MM; Jacob CC; Antunes AMM
    Eur J Pharm Sci; 2018 Jul; 119():70-82. PubMed ID: 29592839
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Editorial. Bioactivation of drugs: enzymes, reactive metabolites and adverse reactions.
    Orhan H
    Curr Med Chem; 2015; 22(4):406-7. PubMed ID: 25515506
    [No Abstract]   [Full Text] [Related]  

  • 18. Selection of new chemical entities with decreased potential for adverse drug reactions.
    Park KB; Dalton-Brown E; Hirst C; Williams DP
    Eur J Pharmacol; 2006 Nov; 549(1-3):1-8. PubMed ID: 16979156
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is it possible to more accurately predict which drug candidates will cause idiosyncratic drug reactions?
    Uetrecht JP
    Curr Drug Metab; 2000 Sep; 1(2):133-41. PubMed ID: 11465079
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.